Back to News
Market Impact: 0.2
UBS Initiates Coverage of Rapport Therapeutics at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 15, 2026, UBS initiated coverage of Rapport Therapeutics with a Buy recommendation; Wolfe Research also initiated coverage that day with an Outperform rating. The article provides no price targets, financial forecasts, or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
RAPP0.60
UBS0.00
More News
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- These tech stocks are a buy ahead of their earnings reports, Bank of America says
- Citi says interest rates may matter more for economy than stock valuations
- AI Selloff Tests Investor Confidence
- Chip Stocks Just Fell 8 Days in a Row, Their Longest Losing Streak Since 2008
- Susan Dell is the one running the Dells’ $10 billion giving operation—and her biggest bets are on kids, health care, and UT Austin